Výsledky vyhledávání - "Ursula Sevelda"

Pain and fertility outcomes of nerve-sparing, full-thickness disk or segmental bowel resection for deep infiltrating endometriosis-A prospective cohort study

Autor: Mee Kristine Aas-Eng, Gernot Hudelist, Mohamad Salama, Ursula Sevelda, Franz Berger, Lisa Kirchner, Bernhard Dauser, Tudor Birsan

Publikováno v: Acta Obstetricia et Gynecologica Scandinavica. 97:1438-1446

Intoduction Choosing the optimal treatment for bowel endometriosis, ie, conservative vs radical surgery, is under debate. We aimed to evaluate the surgical outcomes of segmental resection and disk resection regarding fertility, pain symptoms, and qua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d99e5aaa6d03bd432a0fb0b3ffb95548
https://doi.org/10.1111/aogs.13436

Zobrazit plný text záznamu

Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience

Autor: Catharina Wenzel, Gottfried J. Locker, Rupert Bartsch, Ursula Pluschnig, Dagmar Hussian, Günther G. Steger, Christoph C. Zielinski, Ursula Sevelda, Michael Gnant, Raimund Jakesz

Publikováno v: European Journal of Cancer. 41:2655-2661

Fulvestrant (Faslodex) is a new oestrogen receptor (ER) antagonist with no agonist effects. This report describes the experience of a single centre including 126 postmenopausal women with advanced breast cancer (ABC) in a fulvestrant Compassionate Us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abbd859dfbe6ec2c9d9c9b83a9aaaad5
https://doi.org/10.1016/j.ejca.2005.07.016

Zobrazit plný text záznamu

Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer

Autor: Guenther G. Steger, Michael Gnant, Rupert Bartsch, Catharina Wenzel, Gottfried J. Locker, Dagmar Hussian, Ursula Pluschnig, Raimund Jakesz, Christoph C. Zielinski, Ursula Sevelda

Publikováno v: Anti-Cancer Drugs. 16:441-445

The objective of this pilot trial was to evaluate the safety and activity profile of epidoxorubicin, docetaxel and oral capecitabine plus pegfilgrastim (TEX+P) as preoperative first-line treatment for patients with breast cancer. Eleven consecutive p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6323cb3f784f88af4fab3ec0da72b0c
https://doi.org/10.1097/00001813-200504000-00011

Zobrazit plný text záznamu

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria

Autor: Gerhard Wolfram, Birgit Volgger, Christian Marth, Alain G. Zeimet, Christian Schauer, Edgar Petru, Alexander Reinthaller, Gerhard Bogner, Michaela Klein, Ursula Sevelda-Schwarzgruber

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 25(2)

ObjectiveRecurrent/advanced endometrial carcinoma carries a poor prognosis. Chemotherapy usually consists of cisplatin/doxorubicin and paclitaxel or the doublet of carboplatin and paclitaxel.We report on final results of the Austrian phase 2 AGO tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3e516db88e14236905c638c6e234a1
https://pubmed.ncbi.nlm.nih.gov/25611899

Zobrazit plný text záznamu

Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity

Autor: Ilona Steppan, Alain G. Zeimet, Christian Marth, Ursula Sevelda, Daniel Reimer, Hanno Ulmer

Publikováno v: Chemotherapy. 55(6)

Background: To study the efficacy of pegylated liposomal doxorubicin (PLD) at a modified dose of 45 mg/m2 every 4 weeks in platinum-resistant ovarian cancer and to evaluate toxicities and effects on quality of life (QoL) of this single-agent regimen.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27ec3fea6f3ac33ff0a6706cd43e0773
https://pubmed.ncbi.nlm.nih.gov/19955744

Zobrazit plný text záznamu

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

Autor: Christoph C. Zielinski, Gabriela Altorjai, Robert M. Mader, Gottfried J. Locker, Catharina Wenzel, Ursula Sevelda, Ursula Pluschnig, Dagmar Hussian, Guenther G. Steger, Rupert Bartsch

Publikováno v: BMC Cancer
BMC Cancer, Vol 6, Iss 1, p 81 (2006)

Background At many centres tumour markers are used to detect disease recurrence and to monitor response to therapy in patients with advanced disease, although the real value of serial observation of marker levels remains disputed. In this study, we e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03a59077470e51880d5deb5405dc39a2
https://doi.org/10.1186/1471-2407-6-81

Zobrazit plný text záznamu

Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience

Autor: Guenther G. Steger, Gottfried J. Locker, Ursula Pluschnig, Dagmar Hussian, Catharina Wenzel, Christoph C. Zielinski, Robert M. Mader, Ursula Sevelda, Rupert Bartsch

Publikováno v: Anti-cancer drugs. 16(6)

We evaluated Darbepoetin alpha (Aranesp; Amgen), a novel erythropoietic protein, in patients who developed anemia while receiving chemotherapy. Seventy-five patients (median age 62 years, range 40-81 years) undergoing different cancer chemotherapy re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bc8aca53e536554f9d2bdc46f3c237
https://pubmed.ncbi.nlm.nih.gov/15930888

Zobrazit plný text záznamu

Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial

Autor: Rupert Bartsch, Christoph C. Zielinski, Dagmar Hussian, Catharina Wenzel, Robert M. Mader, Gottfried J. Locker, Ursula Pluschnig, Guenther G. Steger, Ursula Sevelda

Publikováno v: Cancer chemotherapy and pharmacology. 57(5)

Introduction: We evaluated the efficacy of oral vinorelbine (OV) (Navelbine oral® Boeringer-Ingelheim Austria) in patients with advanced breast cancer as first-line therapy or after progressing under earlier line chemotherapies alone or in combinati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fba25b391615461202d017c03a34491
https://pubmed.ncbi.nlm.nih.gov/16133525

Zobrazit plný text záznamu

Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age

Autor: Sami Bassim, Wilfried Feichtinger, Andrea Weghofer, Ursula Sevelda, Elke Beilhack, M. Margreiter

Publikováno v: Fertility and sterility. 81(4)

Objective To determine whether minimal stimulation with short-term application of low-dose recombinant follicle-stimulating hormone (FSH) together with a gonadotropin-releasing hormone (GnRH) antagonist represents a cost-effective treatment regimen f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130a19ee8bf76797d6c60eae277496fd
https://pubmed.ncbi.nlm.nih.gov/15066455

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání